Divalproex Sodium Tablet, Extended Release
Product Images NDC 68788-8358

7 FDA label images from Preferred Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68788-8358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)
Chemical structure of divalproex sodium, showing the valproate ions and sodium ion in the formulation.*
FDA Label Image

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)
A cumulative distribution plot comparing the percentage reduction in CPS rate between Divalproex Sodium Delayed-Release tablets and placebo. The x-axis represents the percentage of patients, and the y-axis shows the percentage reduction in CPS rate, indicating patient improvement or worsening over a range from -100% to 100%. The plot shows Divalproex Sodium results as a solid line and placebo as a dashed line.*
FDA Label Image

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)
A line chart depicting percentage reduction in CPS rate versus percentage of patients for high dose and low dose Divalproex Sodium delayed release. The y-axis shows percentage reduction from -100% to 100%, indicating worsening or improvement, and the x-axis shows percentage of patients from 100 to 0%. Two lines represent patient response distributions for high and low doses.*
FDA Label Image

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)
A bar chart comparing two groups: placebo and divalproex sodium extended-release tablets. The y-axis shows a numerical scale from 0 to 1.2; placebo has a lower value around 0.6, and divalproex sodium tablets have a higher value marked at 1.2, indicating a statistically significant difference noted by an asterisk with a p-value of 0.006.*
FDA Label Image

Image (1fc9a662 2c99 4c65 B31c Ebee40f357aa 201 1)

FDA Label Image

Image (1fc9a662 2c99 4c65 B31c Ebee40f357aa 232 1)

FDA Label Image

Divalproex Sodium Er Tab 500mg (1638e85a 579b 4286 8f77 49f9e6c88488 07)

Divalproex Sodium Er Tab 500mg (1638e85a 579b 4286 8f77 49f9e6c88488 07)
Label for Divalproex Sodium ER Tab 500 mg extended-release tablets by Preferred Pharmaceuticals, Inc. The label highlights the generic name, strength, and dosage form, and includes caution about federal law prohibiting transfer of the drug. It features barcodes, brief usage instructions in English and Spanish, and storage conditions. Manufacturer Lupin Pharmaceuticals, Inc. is mentioned along with placeholder fields for lot, batch, and NDC numbers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.